Perspective from Eugene Shapiro, MD
Disclosures: Dagan reports receiving grants and research support from Merck Sharp & Dohme and Pfizer; being a scientific consultant for MeMed, Merck Sharp & Dohme, and Pfizer; and being a speaker for Pfizer. Please see the study for all other authors’ relevant financial disclosures.
February 28, 2021
2 min read
Save

PCV7, PCV13 vaccines effective against ear infection in young children

Perspective from Eugene Shapiro, MD
Disclosures: Dagan reports receiving grants and research support from Merck Sharp & Dohme and Pfizer; being a scientific consultant for MeMed, Merck Sharp & Dohme, and Pfizer; and being a speaker for Pfizer. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Real-world data demonstrated that two pneumococcal conjugate vaccines, PCV7 and PCV13, protected against complex ear infection in young children, according to study results published in Clinical Infectious Diseases.

“Our study provides a unique opportunity for assessing real-life serotype-specific direct effectiveness of PCV7 and PCV13 against otitis media (OM) in young children,” Ron Dagan, MD, professor of pediatrics and infectious diseases at the Ben-Gurion University of the Negev in Beer-Sheva, Israel, and colleagues wrote.

“While the results with PCV7 are in line with prelicensure efficacy study, no efficacy data are available for PCV13 against OM,” they wrote. “The results provide insight into the level of direct protection afforded by these PCVs post implementation.”

Dagan and colleagues examined vaccine effectiveness of the PCV7 and PCV13 vaccines against various serotypes of OM. They recruited a total of 1,593 children aged 5 to 35 months old, 223 of whom had OM and 1,370 of whom were part of a control group. The researchers conducted their study between October 2009 and July 2013.

They found that OM serotypes 19F and 19A were responsible for 56.1% of all vaccine-serotype OM. PCV7 showed an efficacy of 57.2% against serotype VT7-OM, whereas PCV13 had an efficacy of 77.4%, 67.4%, and 91.3% against serotypes VT13-OM, the six additional non-VT7 serotypes and 19F-OM, respectively. The PCV13 vaccine also showed 91.3% and 85.2% efficacy against the 19F-OM and 3-OM serotypes, respectively.

“For multiple analyses, the case numbers were relatively small, resulting in wide confidence intervals, often making it difficult to draw conclusions for several subgroups,” the researchers wrote. “Nevertheless, this large study adds very valuable information to the limitations.”